Alza Corporation

Medtronic, Inc.

Durect Corporation

Other

Johnson & Johnson Consumer Companies, Inc.

Patrick T. Cahalan

Darrel F. Untereker

Joseph B. Phipps

Kenneth R. Brennen

Mary Southam

Keith J. Bernstein

Henk Noorduin

Joseph B Phipps

Gary A Lattin

Darrel F Untereker

Larry A McNichols

John D Badzinski

Allan H Jevne

Carolann M Holmblad

Warren W Howland

Robert M Gale

Ronald P Haak

Jay Douglas Audett

Paul D Sorenson

Rama V Padmanabhan

Lyn C Moodie

Thomas M Stein

Jane Stepic

Ying Sun

Patrick T Cahalan

Jeffrey M Wu

Jue-Chen Liu

Michel J N Cormier

Michel J Cormier

Kenneth R Brennen

Philip W Ledger

William N Reining

Keith J Bernstein

Juanita A Johnson

Michael J Grace

Stella Chao

Wiliam N Reining

Michael J N Cormier

Larry A Mcnichols

A transdermal analgesic system having reduced potential for abuse, wherein the system provides for the controlled release of the antagonist at a rate sufficient to provide an abuse limiting release rate ratio of the antagonist to the analgesic when the dosage form is subject to abuse is disclosed.

Transdermal analgesic systems with reduced abuse potential

The present invention features a method of treating pores on the skin by applying to skin in need of such treatment a device including a housing having a skin contacting surface, a first conductive electrode, a second conductive electrode, and a carrier; wherein the first conductive electrode is in electric communication with the second conductive electrode, wherein the first conductive electrode is in ionic communication with the carrier, wherein the carrier is in communication with the skin contacting surface, and wherein the skin contacting surface is placed in contact with the skin.

Methods of treating pores on the skin with electricity

An electrotransport device for delivering one or more therapeutic agents through the skin includes electrodes for contacting the skin, at least one electrode containing the agent, a power source for generating electrical current (I) for delivering the agent, a current generating and controlling means and a disabling means for permanently and irreversibly disabling the current. The disabling means may include a timer means, a counter means, or a body parameter sensor and limit comparator to effect permanent disabling. The disabling means may be a permanent transition to a disabled logic state, a permanent discharge of a power supply source, or a permanent diversion of electrotransport current from the electrodes, or a combination of the above. The permanent disabling means may include a circuit connection means having a frangible conducting member which permanently fractures and causes an irreversible open circuit in the connection to the electrodes upon removing a disposable/single use electrode assembly from a reusable portion of an electrotransport device.

Electrotransport delivery device having improved safety and reduced abuse potential

A reservoir and a family of reservoirs are provided which are designed to be used with a single controller to provide a wide range of therapeutic drug delivering regimens while maintaining many of the same reservoir configurations and drug formulations. A method of making a reservoir and a family of reservoirs and incorporating them into an electrotransport system is disclosed.

Methods of electrotransport drug delivery

An electrotransport device () for delivering one or more therapeutic agents through the skin includes electrodes () for contacting the skin (), at least one electrode containing the agent, a power source () for generating electrical current (I) for delivering the agent, a current generating and controlling means (), and a disabling means () for permanently and irreversibly disabling the current. The disabling means () may include a timer means (), a counter means (), or a body parameter sensor () and limit comparator () to effect permanent disabling. The disabling means may be a permanent transition to a disabled logic state, a permanent discharge of a power supply source (), or a permanent diversion of electrotransport current from the electrodes (), or a combination of the above. The permanent disabling means may include a circuit connection means () having a frangible conducting member () which permanently fractures and causes an irreversible open circuit in the connection to the electrodes () upon removing a disposable/single use electrode assembly () from a reusable portion of an electrotransport device.

Reservoir and a series of related reservoirs for use in an electrotransport drug delivery device and devices comprised thereof

The invention provides an improved electrotransport drug delivery system for analgesic drugs, namely fentanyl and sufentanil. The fentanyl/sufentanil is provided as a water soluble salt (eg, fentanyl hydrochloride) dispersed in a hydrogel formulation for use in an electrotransport device (). In accordance with one aspect of the invention, the concentration of fentanyl/sufentanil in the donor reservoir () solution is above a predetermined minimum concentration, whereby the transdermal electrotransport flux of fentanyl/sufentanil is maintained independent of the concentration of fentanyl/sufentanil in solution. In accordance with a second aspect of the present invention, the donor reservoir () of the electrotransport delivery device () is comprised of silver and the donor reservoir () contains a predetermined 'excess' loading of fentanyl/sufentanil halide to prevent silver ion migration with attendant skin discoloration. In accordance with a third aspect of the present invention, a transdermal electrotransport delivered dose of fentanyl/sufentanil is provided which is sufficient to induce analgesia in (eg, adult) human patients suffering from moderate-to-severe pain associated with major surgical procedures.

Method and device for transdermal electrotransport delivery of fentanyl and sufentanil

Methods for conducting operation of an electrode arrangement are described. The methods generally concern use of an electrode reservoir containing both a first electrode and a secondary electrode. A system for practicing the methods is also provided.

Method and apparatus for controlled environment electrotransport

Improved methods of ionophoretic drug delivery are described. By the intentional selection of drug(s) with specific characteristics, of ionotophoresis device, components or both permits the efficiency of drug delivery is increased.

Iontophoretic drug delivery

An electrotransport delivery device utilizing reservoir buffering at a select pH ranges in order to reduce skin irritation and skin resistance is provided. Cathodic reservoirs are buffered to a pH of less than about 4, preferably to a pH in the range of about 2 to 4, while anodic reservoirs are buffered to a pH above about 4, preferably to a pH in the range of about 4 to 10. Another electrotransport delivery device utilizes a potassium sensor to monitor potassium efflux from the skin. Potassium efflux above a certain predetermined level has been found to be a precursor to skin irritation/erythema. Operation of the device is modified (eg, terminated) when the predetermined potassium efflux level is sensed.

Reduction of skin irritation and resistance during electrotransport

Methods for conducting controlled environment electrotransport are described. The methods generally concern control of the ionic environment of the active electrode reservoir, in an electrotransport system. This control may be utilized, for example, to maintain a constant extraneous ion presence, such as pH. It may also be applied in a preferred manner to maintain selected control over the delivery rate of a target species, in time, in the presence of extraneous ions. Apparatus usable to provide for controlled environment electrotransport are also described. In general the apparatus comprises an electrotransport system including an active electrode reservoir having therein both a primary electrode arrangement and a secondary electrode arrangement, with a control arrangement for selected operation of both. The secondary electrode arrangement, being operated different from the primary electrode arrangement, is selected for operation to selectively enhance or otherwise modify ion presence in the active electrode reservoir, to achieve application of the general methods described. The apparatus may include a sensor means therein, for use as feedback to a control system during operation. Methods and systems involving diffusion type delivery are also described.

Growing community of inventors

Plymouth, MN, United States of America

Joseph B Phipps